Literature DB >> 23097329

Stem cell-based therapy for Huntington's disease.

Christof Maucksch1, Elena M Vazey, Renee J Gordon, Bronwen Connor.   

Abstract

Huntington's disease (HD) is a late-onset neurodegenerative disease characterized by a progressive loss of medium spiny neurons in the basal ganglia. The development of stem cell-based therapies for HD aims to replace lost neurons and/or to prevent cell death. This review will discuss pre-clinical studies which have utilized stem or progenitor cells for transplantation therapy using HD animal models. In several studies, neural stem and progenitor cells used as allotransplants and xenografts have been shown to be capable of surviving transplantation and differentiating into mature GABAergic neurons, resulting in behavioral improvements. Beneficial effects have also been reported for transplantation of stem cells derived from non-neural tissue, for example, mesenchymal- and adipose-derived stem cells, which have mainly been attributed to their secretion of growth and neurotrophic factors. Finally, we review studies using stem cells genetically engineered to over-express defined neurotrophic factors. While these studies prove the potential of stem cells for transplantation therapy in HD, it also becomes clear that technical and ethical issues regarding the availability of stem cells must be solved before human trials can be conducted.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23097329     DOI: 10.1002/jcb.24432

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  15 in total

Review 1.  Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders.

Authors:  I M Carvalho; P B Coelho; P C Costa; C S Marques; R S Oliveira; D C Ferreira
Journal:  Neuromolecular Med       Date:  2015-09-15       Impact factor: 3.843

2.  Fate of Neural Progenitor Cells Transplanted Into Jaundiced and Nonjaundiced Rat Brains.

Authors:  Fu-Chen Yang; Sean M Riordan; Michelle Winter; Li Gan; Peter G Smith; Jay L Vivian; Steven M Shapiro; John A Stanford
Journal:  Cell Transplant       Date:  2017-02-03       Impact factor: 4.064

Review 3.  Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support.

Authors:  Samuel E Marsh; Mathew Blurton-Jones
Journal:  Neurochem Int       Date:  2017-02-20       Impact factor: 3.921

4.  Selective A2A receptor antagonist SCH 58261 modulates striatal oxidative stress and alleviates toxicity induced by 3-Nitropropionic acid in male Wistar rats.

Authors:  Cristiani F Bortolatto; Angélica S Reis; Mikaela P Pinz; Guilherme T Voss; Renata L Oliveira; Ane G Vogt; Silvane Roman; Cristiano R Jesse; Cristiane Luchese; Ethel A Wilhelm
Journal:  Metab Brain Dis       Date:  2017-08-09       Impact factor: 3.584

Review 5.  Current and Possible Future Therapeutic Options for Huntington's Disease.

Authors:  Mackenzie W Ferguson; Connor J Kennedy; Thulani H Palpagama; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  J Cent Nerv Syst Dis       Date:  2022-05-21

Review 6.  Advances in treatment of neurodegenerative diseases: Perspectives for combination of stem cells with neurotrophic factors.

Authors:  Jie Wang; Wei-Wei Hu; Zhi Jiang; Mei-Jiang Feng
Journal:  World J Stem Cells       Date:  2020-05-26       Impact factor: 5.326

7.  Stem cell therapy for the treatment of parasitic infections: is it far away?

Authors:  Yan Zhang; Jing-Yi Mi; Yong-Jun Rui; Yong-Liang Xu; Wei Wang
Journal:  Parasitol Res       Date:  2013-11-26       Impact factor: 2.289

Review 8.  Possible protective action of neurotrophic factors and natural compounds against common neurodegenerative diseases.

Authors:  Tadahiro Numakawa
Journal:  Neural Regen Res       Date:  2014-08-15       Impact factor: 5.135

Review 9.  Targeting the vasculature to improve neural progenitor transplant survival.

Authors:  Justin Hill; John Cave
Journal:  Transl Neurosci       Date:  2015-08-27       Impact factor: 1.757

10.  Inhibition of Sox2 Expression in the Adult Neural Stem Cell Niche In Vivo by Monocationic-based siRNA Delivery.

Authors:  Sylvie Remaud; Silvia Alejandra López-Juárez; Anne-Laure Bolcato-Bellemin; Patrick Neuberg; Fabrice Stock; Marie-Elise Bonnet; Rym Ghaddab; Marie Stéphanie Clerget-Froidevaux; Jacqueline Pierre-Simons; Patrick Erbacher; Barbara A Demeneix; Ghislaine Morvan-Dubois
Journal:  Mol Ther Nucleic Acids       Date:  2013-04-23       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.